A Longitudinal Observational Cohort Study to Assess Sustained Immunogenicity up to 48 Months to Quadrivalent Human Papillomavirus Vaccine Among HIV-infected Girls and Boys Age 9-14 Years in Kenya
Latest Information Update: 11 May 2022
Price :
$35 *
At a glance
- Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
- Indications Human papillomavirus infections
- Focus Pharmacodynamics
- 20 Jan 2021 Results of extended follow up analysis assessing the antibody responses to prophylactic quadrivalent human papillomavirus
- 01 Jul 2019 Status changed from active, no longer recruiting to completed.
- 01 Jul 2019 Status changed from active, no longer recruiting to completed.